Under Surveillance  

Oleh:

[s.n]

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 1 (Jan. 2005), page 1-2.
Topik: survey; surveillance

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.2 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Numerologists might point out that a drug named VIOXX was more than likely to suffer a reverse in 2004 (20-O-4). Indeed the non US trade name of the drug, CEOXX, perhaps might also have served as a warning for ray gilmartin, the head of merck, frippery aside, merck's highly publicized withdrawal of refocoxib (Vioxx) in recent weeks and growing concerns over other cycloxygenase 2 (COX2) inhibitors (e.g. Pfizer's celecoxib (Celebrex) and valdecoxib (Bextra) are prompting increasingly strident calls for revisions to postmarketing surveillance and to the FDA's supervision of the process. Biotech companies should take note. Although most of the prominent drug withdrawals have involved pharma in recent years, the problem is equally relevant to smaller companies that are foolish enough to get involved in drugs for chronic conditions with large markets and large patient populations (e.g. insomnia, diabetes, daytime sleepiness), rather than orphan indications and cancer...

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali